; and (V) include a signed certification that the posted data is complete and accurate. (iii) Delayed posting of cost data and extensions (I) Seeking initial approval of drug, or approval of a new use If the responsible party for an applicable drug clinical trial submits a certification that paragraph (3)(E)(iv) or paragraph (3)(E)(v) applies to such trial, the responsible party shall post cost data under clause (i) at the time that clinical trial information is required to be submitted under the applicable paragraph. (II) Extension for good cause The Director of NIH may provide an extension of the deadline for posting of cost data under clause (i) if the responsible party for the trial submits to the Director a written request that demonstrates good cause for the extension and provides an estimate of the date on which the information will be posted. The Director of NIH may grant more than one such extension for a clinical trial, but under no circumstances shall an extension under this subclause extend beyond the date that is 18 months after the completion date of the trial. (III) Extension to establish necessary infrastructure If necessary to establish the necessary infrastructure to accept, organize, and post cost data submitted under clause (i), the Director of NIH may extend the deadline for the posting of cost data under clause (i) to not later than 2 years after the date of enactment of the Pharmaceutical Research Transparency Act of 2023 . (IV) Rule of construction This clause shall not be construed to have any effect on reporting obligations of the responsible party under provisions other than this paragraph. (D) Linking to cost data repository (i) Creation of field The Director of NIH shall create a field within the registry and results data bank to include an electronic link to the relevant cost data posting under subparagraph (C)(i). (ii) Posting The responsible party for an applicable drug clinical trial shall post in the field created under clause (i) a link to the relevant cost data posting no later